लोड हो रहा है...
Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma
For nearly a decade, sorafenib has served as a first-line chemotherapeutic drug for the treatment of hepatocellular carcinoma (HCC), but it displays only limited efficacy against advanced drug-resistant HCC. Regorafenib, the first second-line drug approved for treatment after sorafenib failure, can...
में बचाया:
| में प्रकाशित: | Aging (Albany NY) |
|---|---|
| मुख्य लेखकों: | , , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Impact Journals
2020
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7746348/ https://ncbi.nlm.nih.gov/pubmed/33203790 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/aging.104028 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|